Internal genes of a highly pathogenic H5N1 influenza virus determine high viral replication in myeloid cells and severe outcome of infection in mice

PLoS Pathogens

Volumn 14, Issue 1, 2018, Pages

  Li, Hui ^a,b   Bradley, Konrad C ^b,d   Long, Jason S ^b   Frise, Rebecca ^b   Ashcroft, Jonathan W ^b,e   Hartgroves, Lorian C ^b   Shelton, Holly ^b,f   Makris, Spyridon ^c   Johansson, Cecilia ^c   Cao, Bin ^a   Barclay, Wendy S ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^d THE FRANCIS CRICK INSTITUTE   (United Kingdom)

^e PHE Porton   (United Kingdom)

^f INSTITUTE FOR ANIMAL HEALTH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CHEMOKINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT LOSS; BONE MARROW CELL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENETIC TRANSFECTION; HEMAGGLUTINATION TEST; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOLOGY; INFLUENZA A (H5N1); INFLUENZA A VIRUS (H5N1); INNATE IMMUNITY; MOUSE; NONHUMAN; PATHOGENICITY; PLAQUE ASSAY; POLYMERASE CHAIN REACTION; RNA EXTRACTION; RNA REPLICATION; VIRUS LOAD; VIRUS REPLICATION; A-549 CELL LINE; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CELL CULTURE; DOG; GENETICS; HEK293 CELL LINE; HUMAN; IMMUNOLOGY; INFLUENZA; KNOCKOUT MOUSE; MDCK CELL LINE; METABOLISM; MORTALITY; ORTHOMYXOVIRUS INFECTION; PHYSIOLOGY; SEVERITY OF ILLNESS INDEX; VIROLOGY; VIRUS GENE;

A549 CELLS; ANIMALS; CELLS, CULTURED; DOGS; FEMALE; GENES, VIRAL; HEK293 CELLS; HUMANS; IMMUNITY, INNATE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA, HUMAN; MADIN DARBY CANINE KIDNEY CELLS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOID CELLS; ORTHOMYXOVIRIDAE INFECTIONS; SEVERITY OF ILLNESS INDEX; VIRUS REPLICATION;

EID: 85041549209     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1006821     Document Type: Article

References (82)

1. Wang C, Yu H, Horby PW, Cao B, Wu P, Yang S, et al. Comparison of patients hospitalized with influenza A subtypes H7N9, H5N1, and 2009 pandemic H1N1. Clin Infect Dis. 2014; 58(8):1095–1103. doi: 10.1093/cid/ciu053 24488975.
2. Zhang YH, Zhao Y, Li N, Peng YC, Giannoulatou E, Jin RH, et al. Interferon-induced transmembrane protein-3 genetic variant rs12252-C is associated with severe influenza in Chinese individuals. Nat Commun. 2013; 4 1418. doi: 10.1038/ncomms2433 23361009.
3. Hagan M, Ranadheera C, Audet J, Morin J, Leung A, Kobasa D, Post-exposure treatment with whole inactivated H5N1 avian influenza virus protects against lethal homologous virus infection in mice. Sci Rep. 2016; 629433. doi: 10.1038/srep29433 27405487.
4. Sridhar S, Begom S, Bermingham A, Hoschler K, Adamson W, Carman W, et al. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med. 2013; 19(10):1305–1312. doi: 10.1038/nm.3350 24056771.
5. Watanabe T, Kawaoka Y, Pathogenesis of the 1918 pandemic influenza virus. PLoS Pathog. 2011; 7(1):e1001218. doi: 10.1371/journal.ppat.1001218 21298032.
6. Cumulative number of confirmed human cases of avian influenza A(H5N1) reported to WHO. Retrieved 10 February, 2017
7. de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, Chau TN, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med. 2006; 12(10):1203–1207. doi: 10.1038/nm1477 16964257.
8. Chan MC, Cheung CY, Chui WH, Tsao SW, Nicholls JM, Chan YO, et al. Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells. Respir Res. 2005; 6 135. doi: 10.1186/1465-9921-6-135 16283933.
9. Peiris JS, Yu WC, Leung CW, Cheung CY, Ng WF, Nicholls JM, et al. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet. 2004; 363(9409):617–619. doi: 10.1016/S0140-6736(04)15595-5 14987888.
10. Cheung CY, Poon LL, Lau AS, Luk W, Lau YL, Shortridge KF, et al. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease?Lancet. 2002; 360(9348):1831–1837. 12480361.
11. Hui KP, Lee SM, Cheung CY, Ng IH, Poon LL, Guan Y, et al. Induction of proinflammatory cytokines in primary human macrophages by influenza A virus (H5N1) is selectively regulated by IFN regulatory factor 3 and p38 MAPK. J Immunol. 2009; 182(2):1088–1098. 19124752.
12. Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, Hayden FG, Nguyen DH, de Jong MD, et al. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med. 2008; 358(3):261–273. doi: 10.1056/NEJMra0707279 18199865.
13. Mori M, Rothman AL, Kurane I, Montoya JM, Nolte KB, Norman JE, et al. High levels of cytokine-producing cells in the lung tissues of patients with fatal hantavirus pulmonary syndrome. J Infect Dis. 1999; 179(2):295–302. doi: 10.1086/314597 9878011.
14. Safronetz D, Prescott J, Feldmann F, Haddock E, Rosenke R, Okumura A, et al. Pathophysiology of hantavirus pulmonary syndrome in rhesus macaques. Proc Natl Acad Sci U S A. 2014; 111(19):7114–7119. doi: 10.1073/pnas.1401998111 24778254.
15. Rothman AL, Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol. 2011; 11(8):532–543. doi: 10.1038/nri3014 21760609.
16. Imai M, Herfst S, Sorrell EM, Schrauwen EJ, Linster M, De Graaf M, et al. Transmission of influenza A/H5N1 viruses in mammals. Virus Res. 2013; 178(1):15–20. doi: 10.1016/j.virusres.2013.07.017 23954580.
17. Herfst S, Schrauwen EJ, Linster M, Chutinimitkul S, de Wit E, Munster VJ, et al. Airborne transmission of influenza A/H5N1 virus between ferrets. Science. 2012; 336(6088):1534–1541. doi: 10.1126/science.1213362 22723413.
18. Goritzka M, Makris S, Kausar F, Durant LR, Pereira C, Kumagai Y, et al. Alveolar macrophage-derived type I interferons orchestrate innate immunity to RSV through recruitment of antiviral monocytes. J Exp Med. 2015; 212(5):699–714. doi: 10.1084/jem.20140825 25897172.
19. Goritzka M, Durant LR, Pereira C, Salek-Ardakani S, Openshaw PJ, Johansson C, Alpha/beta interferon receptor signaling amplifies early proinflammatory cytokine production in the lung during respiratory syncytial virus infection. J Virol. 2014; 88(11):6128–6136. doi: 10.1128/JVI.00333-14 24648449.
20. Davidson S, Crotta S, McCabe TM, Wack A, Pathogenic potential of interferon alphabeta in acute influenza infection. Nat Commun. 2014; 5 3864. doi: 10.1038/ncomms4864 24844667.
21. Pulendran B, Maddur MS, Innate immune sensing and response to influenza. Curr Top Microbiol Immunol. 2015; 386 23–71. doi: 10.1007/82_2014_405 25078919.
22. Iwasaki A, Pillai PS, Innate immunity to influenza virus infection. Nat Rev Immunol. 2014; 14(5):315–328. doi: 10.1038/nri3665 24762827.
23. Rajsbaum R, Albrecht RA, Wang MK, Maharaj NP, Versteeg GA, Nistal-Villan E, et al. Species-specific inhibition of RIG-I ubiquitination and IFN induction by the influenza A virus NS1 protein. PLoS Pathog. 2012; 8(11):e1003059. doi: 10.1371/journal.ppat.1003059 23209422.
24. Loo YM, Fornek J, Crochet N, Bajwa G, Perwitasari O, Martinez-Sobrido L, et al. Distinct RIG-I and MDA5 signaling by RNA viruses in innate immunity. J Virol. 2008; 82(1):335–345. doi: 10.1128/JVI.01080-07 17942531.
25. Nemeroff ME, Barabino SM, Li Y, Keller W, Krug RM, Influenza virus NS1 protein interacts with the cellular 30 kDa subunit of CPSF and inhibits 3'end formation of cellular pre-mRNAs. Mol Cell. 1998; 1(7):991–1000. 9651582.
26. Hatada E, Fukuda R, Binding of influenza A virus NS1 protein to dsRNA in vitro. J Gen Virol. 1992; 73 (Pt 12) 3325–3329. doi: 10.1099/0022-1317-73-12-3325 1469370
27. Wang W, Riedel K, Lynch P, Chien CY, Montelione GT, Krug RM, RNA binding by the novel helical domain of the influenza virus NS1 protein requires its dimer structure and a small number of specific basic amino acids. Rna. 1999; 5(2):195–205. 10024172.
28. Jia D, Rahbar R, Chan RW, Lee SM, Chan MC, Wang BX, et al. Influenza virus non-structural protein 1 (NS1) disrupts interferon signaling. PLoS One. 2010; 5(11):e13927. doi: 10.1371/journal.pone.0013927 21085662.
29. Menachery VD, Eisfeld AJ, Schafer A, Josset L, Sims AC, Proll S, et al. Pathogenic influenza viruses and coronaviruses utilize similar and contrasting approaches to control interferon-stimulated gene responses. MBio. 2014; 5(3):e01174–01114. doi: 10.1128/mBio.01174-14 24846384.
30. Ludwig S, Schultz U, Mandler J, Fitch WM, Scholtissek C, Phylogenetic relationship of the nonstructural (NS) genes of influenza A viruses. Virology. 1991; 183(2):566–577. 1830182.
31. Hayman A, Comely S, Lackenby A, Hartgroves LC, Goodbourn S, McCauley JW, et al. NS1 proteins of avian influenza A viruses can act as antagonists of the human alpha/beta interferon response. J Virol. 2007; 81(5):2318–2327. doi: 10.1128/JVI.01856-06 P 17182679.
32. Wu NC, Young AP, Al-Mawsawi LQ, Olson CA, Feng J, Qi H, et al. High-throughput identification of loss-of-function mutations for anti-interferon activity in the influenza A virus NS segment. J Virol. 2014; 88(17):10157–10164. doi: 10.1128/JVI.01494-14 24965464.
33. Matthaei M, Budt M, Wolff T, Highly pathogenic H5N1 influenza A virus strains provoke heterogeneous IFN-alpha/beta responses that distinctively affect viral propagation in human cells. PLoS One. 2013; 8(2):e56659. doi: 10.1371/journal.pone.0056659 23451066.
34. Twu KY, Kuo RL, Marklund J, Krug RM, The H5N1 influenza virus NS genes selected after 1998 enhance virus replication in mammalian cells. J Virol. 2007; 81(15):8112–8121. doi: 10.1128/JVI.00006-07 17522219.
35. Kawaoka Y, Webster RG, Sequence requirements for cleavage activation of influenza virus hemagglutinin expressed in mammalian cells. Proc Natl Acad Sci U S A. 1988; 85(2):324–328. 2829180.
36. Hatta M, Gao P, Halfmann P, Kawaoka Y, Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses. Science. 2001; 293(5536):1840–1842. doi: 10.1126/science.1062882 11546875.
37. Tundup S, Kandasamy M, Perez JT, Mena N, Endothelial cell tropism is a determinant of H5N1 pathogenesis in mammalian species. 2017; 13(3):e1006270. doi: 10.1371/journal.ppat.1006270 28282445.
38. Tumpey TM, Basler CF, Aguilar PV, Zeng H, Solorzano A, Swayne DE, et al. Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science. 2005; 310(5745):77–80. doi: 10.1126/science.1119392 16210530.
39. Ramos I, Bernal-Rubio D, Durham N, Belicha-Villanueva A, Lowen AC, Steel J, et al. Effects of receptor binding specificity of avian influenza virus on the human innate immune response. J Virol. 2011; 85(9):4421–4431. doi: 10.1128/JVI.02356-10 PMID:Pmc3126224. 21345953.
40. Sun X, Zeng H, Kumar A, Belser JA, Maines TR, Tumpey TM, Constitutively Expressed IFITM3 Protein in Human Endothelial Cells Poses an Early Infection Block to Human Influenza Viruses. J Virol. 2016; 90(24):11157–11167. doi: 10.1128/JVI.01254-16 27707929.
41. Imai Y, Kuba K, Neely GG, Yaghubian-Malhami R, Perkmann T, van Loo G, et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell. 2008; 133(2):235–249. doi: 10.1016/j.cell.2008.02.043 18423196.
42. Cline TD, Karlsson EA, Freiden P, Seufzer BJ, Rehg JE, Webby RJ, et al. Increased pathogenicity of a reassortant 2009 pandemic H1N1 influenza virus containing an H5N1 hemagglutinin. J Virol. 2011; 85(23):12262–12270. doi: 10.1128/JVI.05582-11 21917948.
43. Kobasa D, Takada A, Shinya K, Hatta M, Halfmann P, Theriault S, et al. Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus. Nature. 2004; 431(7009):703–707. doi: 10.1038/nature02951 15470432
44. Carlson CM, Turpin EA, Moser LA, O'Brien KB, Cline TD, Jones JC, et al. Transforming growth factor-beta: activation by neuraminidase and role in highly pathogenic H5N1 influenza pathogenesis. PLoS Pathog. 2010; 6(10):e1001136. doi: 10.1371/journal.ppat.1001136 P 20949074.
45. Goto H, Kawaoka Y, A novel mechanism for the acquisition of virulence by a human influenza A virus. Proc Natl Acad Sci U S A. 1998; 95(17):10224–10228. 9707628.
46. Hessel A, Savidis-Dacho H, Coulibaly S, Portsmouth D, Kreil TR, Crowe BA, et al. MVA vectors expressing conserved influenza proteins protect mice against lethal challenge with H5N1, H9N2 and H7N1 viruses. PLoS One. 2014; 9(2):e88340. doi: 10.1371/journal.pone.0088340 24523886.
47. Weinheimer VK, Becher A, Tonnies M, Holland G, Knepper J, Bauer TT, et al. Influenza A viruses target type II pneumocytes in the human lung. J Infect Dis. 2012; 206(11):1685–1694. doi: 10.1093/infdis/jis455 22829640.
48. Knepper J, Schierhorn KL, Becher A, Budt M, Tonnies M, Bauer TT, et al. The novel human influenza A(H7N9) virus is naturally adapted to efficient growth in human lung tissue. MBio. 2013; 4(5):e00601–00613. doi: 10.1128/mBio.00601-13 PMID:Pmc3791893. 24105764.
49. Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD, Human and avian influenza viruses target different cell types in cultures of human airway epithelium. Proc Natl Acad Sci U S A. 2004; 101(13):4620–4624. doi: 10.1073/pnas.0308001101 15070767.
50. Shelton H, Smith M, Hartgroves L, Stilwell P, Roberts K, Johnson B, et al. An influenza reassortant with polymerase of pH1N1 and NS gene of H3N2 influenza A virus is attenuated in vivo. J Gen Virol. 2012; 93(Pt 5):998–1006. doi: 10.1099/vir.0.039701-0 22323532.
51. Kallfass C, Lienenklaus S, Weiss S, Staeheli P, Visualizing the beta interferon response in mice during infection with influenza A viruses expressing or lacking nonstructural protein 1. J Virol. 2013; 87(12):6925–6930. doi: 10.1128/JVI.00283-13 23576514.
52. Cella M, Jarrossay D, Facchetti F, Alebardi O, Nakajima H, Lanzavecchia A, et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med. 1999; 5(8):919–923. doi: 10.1038/11360 10426316
53. Ciancanelli MJ, Huang SX, Luthra P, Garner H, Itan Y, Volpi S, et al. Infectious disease. Life-threatening influenza and impaired interferon amplification in human IRF7 deficiency. Science. 2015; 348(6233):448–453. doi: 10.1126/science.aaa1578 25814066.
54. Alsharifi M, Mullbacher A, Regner M, Interferon type I responses in primary and secondary infections. Immunol Cell Biol. 2008; 86(3):239–245. doi: 10.1038/sj.icb.7100159 18180794.
55. Helft J, Manicassamy B, Guermonprez P, Hashimoto D, Silvin A, Agudo J, et al. Cross-presenting CD103+ dendritic cells are protected from influenza virus infection. J Clin Invest. 2012; 122(11):4037–4047. doi: 10.1172/JCI60659 23041628.
56. Langlois RA, Varble A, Chua MA, Garcia-Sastre A, tenOever BR, Hematopoietic-specific targeting of influenza A virus reveals replication requirements for induction of antiviral immune responses. Proc Natl Acad Sci U S A. 2012; 109(30):12117–12122. doi: 10.1073/pnas.1206039109 22778433.
57. Thor SW, Nguyen H, Balish A, Hoang AN, Gustin KM, Nhung PT, et al. Detection and Characterization of Clade 1 Reassortant H5N1 Viruses Isolated from Human Cases in Vietnam during 2013. PLoS One. 2015; 10(8):e0133867. doi: 10.1371/journal.pone.0133867 26244768.
58. Manabe T, Yamaoka K, Tango T, Binh NG, Co DX, Tuan ND, et al. Chronological, geographical, and seasonal trends of human cases of avian influenza A (H5N1) in Vietnam, 2003–2014: a spatial analysis. BMC Infect Dis. 2016; 16 64. doi: 10.1186/s12879-016-1391-8 26847341.
59. Mathur MB, Patel RB, Gould M, Uyeki TM, Bhattacharya J, Xiao Y, et al. Seasonal patterns in human A (H5N1) virus infection: analysis of global cases. PLoS One. 2014; 9(9):e106171. doi: 10.1371/journal.pone.0106171 PMID:Pmc4162536. 25215608
60. Bradley KC, Galloway SE, Lasanajak Y, Song X, Heimburg-Molinaro J, Yu H, et al. Analysis of influenza virus hemagglutinin receptor binding mutants with limited receptor recognition properties and conditional replication characteristics. J Virol. 2011; 85(23):12387–12398. doi: 10.1128/JVI.05570-11 21917953.
61. Kumari K, Gulati S, Smith DF, Gulati U, Cummings RD, Air GM, Receptor binding specificity of recent human H3N2 influenza viruses. Virol J. 2007; 4 42. doi: 10.1186/1743-422X-4-42 17490484.
62. Stevens J, Blixt O, Tumpey TM, Taubenberger JK, Paulson JC, Wilson IA, Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus. Science. 2006; 312(5772):404–410. doi: 10.1126/science.1124513 16543414.
63. DuBois RM, Zaraket H, Reddivari M, Heath RJ, White SW, Russell CJ, Acid stability of the hemagglutinin protein regulates H5N1 influenza virus pathogenicity. PLoS Pathog. 2011; 7(12):e1002398. doi: 10.1371/journal.ppat.1002398 22144894.
64. Jia N, Barclay WS, Roberts K, Yen HL, Chan RW, Lam AK, et al. Glycomic characterization of respiratory tract tissues of ferrets: implications for its use in influenza virus infection studies. J Biol Chem. 2014; 289(41):28489–28504. doi: 10.1074/jbc.M114.588541 25135641.
65. Sakabe S, Takano R, Nagamura-Inoue T, Yamashita N, Nidom CA, Quynh Le M, et al. Differences in cytokine production in human macrophages and in virulence in mice are attributable to the acidic polymerase protein of highly pathogenic influenza A virus subtype H5N1. J Infect Dis. 2013; 207(2):262–271. doi: 10.1093/infdis/jis523 PMID:Pmc3611767. 23042757
66. Mok KP, Wong CH, Cheung CY, Chan MC, Lee SM, Nicholls JM, et al. Viral genetic determinants of H5N1 influenza viruses that contribute to cytokine dysregulation. J Infect Dis. 2009; 200(7):1104–1112. doi: 10.1086/605606 19694514.
67. Waddell SJ, Popper SJ, Rubins KH, Griffiths MJ, Brown PO, Levin M, et al. Dissecting interferon-induced transcriptional programs in human peripheral blood cells. PLoS One. 2010; 5(3):e9753. doi: 10.1371/journal.pone.0009753 20339534.
68. Helft J, Bottcher JP, Chakravarty P, Zelenay S, Huotari J, Schraml BU, et al. Alive but Confused: Heterogeneity of CD11c(+) MHC Class II(+) Cells in GM-CSF Mouse Bone Marrow Cultures. Immunity. 2016; 44(1):3–4. doi: 10.1016/j.immuni.2015.12.014 26789913
69. Zeng H, Goldsmith C, Thawatsupha P, Chittaganpitch M, Waicharoen S, Zaki S, et al. Highly pathogenic avian influenza H5N1 viruses elicit an attenuated type i interferon response in polarized human bronchial epithelial cells. J Virol. 2007; 81(22):12439–12449. doi: 10.1128/JVI.01134-07 17855549.
70. Bao Y, Bolotov P, Dernovoy D, Kiryutin B, Zaslavsky L, Tatusova T, et al. The influenza virus resource at the National Center for Biotechnology Information. J Virol. 2008; 82(2):596–601. doi: 10.1128/JVI.02005-07 PMID:Pmc2224563. 17942553
71. Rehwinkel J, Tan CP, Goubau D, Schulz O, Pichlmair A, Bier K, et al. RIG-I detects viral genomic RNA during negative-strand RNA virus infection. Cell. 2010; 140(3):397–408. doi: 10.1016/j.cell.2010.01.020 20144762.
72. Baum A, Sachidanandam R, Garcia-Sastre A, Preference of RIG-I for short viral RNA molecules in infected cells revealed by next-generation sequencing. Proc Natl Acad Sci U S A. 2010; 107(37):16303–16308. doi: 10.1073/pnas.1005077107 20805493.
73. Killip MJ, Smith M, Jackson D, Randall RE, Activation of the interferon induction cascade by influenza a viruses requires viral RNA synthesis and nuclear export. J Virol. 2014; 88(8):3942–3952. doi: 10.1128/JVI.03109-13 24478437.
74. Hayman A, Comely S, Lackenby A, Murphy S, McCauley J, Goodbourn S, et al. Variation in the ability of human influenza A viruses to induce and inhibit the IFN-beta pathway. Virology. 2006; 347(1):52–64. doi: 10.1016/j.virol.2005.11.024 16378631.
75. Long JS, Giotis ES, Moncorge O, Frise R, Mistry B, James J, et al. Species difference in ANP32A underlies influenza A virus polymerase host restriction. Nature. 2016; 529(7584):101–104. doi: 10.1038/nature16474 26738596.
76. Elleman CJ, Barclay WS, The M1 matrix protein controls the filamentous phenotype of influenza A virus. Virology. 2004; 321(1):144–153. doi: 10.1016/j.virol.2003.12.009 15033573
77. Langlois RA, Albrecht RA, Kimble B, Sutton T, Shapiro JS, Finch C, et al. MicroRNA-based strategy to mitigate the risk of gain-of-function influenza studies. Nat Biotechnol. 2013; 31(9):844–847. doi: 10.1038/nbt.2666 23934176.
78. Kumagai Y, Takeuchi O, Kato H, Kumar H, Matsui K, Morii E, et al. Alveolar macrophages are the primary interferon-alpha producer in pulmonary infection with RNA viruses. Immunity. 2007; 27(2):240–252. doi: 10.1016/j.immuni.2007.07.013 17723216
79. Gilliet M, Boonstra A, Paturel C, Antonenko S, Xu XL, Trinchieri G, et al. The development of murine plasmacytoid dendritic cell precursors is differentially regulated by FLT3-ligand and granulocyte/macrophage colony-stimulating factor. J Exp Med. 2002; 195(7):953–958. doi: 10.1084/jem.20020045 11927638.
80. Naik SH, Proietto AI, Wilson NS, Dakic A, Schnorrer P, Fuchsberger M, et al. Cutting edge: generation of splenic CD8+ and CD8- dendritic cell equivalents in Fms-like tyrosine kinase 3 ligand bone marrow cultures. J Immunol. 2005; 174(11):6592–6597. 15905497
81. Brawand P, Fitzpatrick DR, Greenfield BW, Brasel K, Maliszewski CR, De Smedt T, Murine plasmacytoid pre-dendritic cells generated from Flt3 ligand-supplemented bone marrow cultures are immature APCs. J Immunol. 2002; 169(12):6711–6719. 12471102
82. Huang Q, Li L, Lin Z, Xu W, Han S, Zhao C, et al. Identification of Preferentially Expressed Antigen of Melanoma as a Potential Tumor Suppressor in Lung Adenocarcinoma. Med Sci Monit. 2016; 22 1837–1842. doi: 10.12659/MSM.895642 27241212.